Quest to shutter Michigan lab, let go of 57 workers in coming months

quest diagnostics_exam one_whitepaper_oct16
Quest Diagnostics will close its lab in Troy, Michigan, laying off 57 workers at the facility. (Quest)

Quest Diagnostics, the New Jersey-based diagnostics maker, will close its Troy, Michigan, laboratory by early May, laying off 57 workers at the facility.

The company, which provides clinical lab services, operates four labs in Michigan that employ about 540 people. Some employees at the Troy site will be eligible to apply for jobs at other locations, Crain’s Detroit Business reported.

"As our company responds to market forces and reimbursement challenges, we have determined we can be more efficient by reducing touch points in our testing process," Denny Moynihan, a company spokesman, told Crain’s.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Quest acquired Summit Health in 2014, which, at the time, employed about 175 workers across the U.S.

Last July, Quest completed its acquisition of two laboratory businesses in Texas, establishing a foothold in the southwestern U.S. with a new national “center of excellence” for cancer precision diagnostics.It was part of the company’s move to scale up in precision medicine.

Since President Barack Obama announced the Precision Medicine Initiative in 2015, several other players have been working to scale precision medicine, such as San Francisco-based Dignity Health and Catholic Health Initiatives in Colorado.

Suggested Articles

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

A new $100 million (€85 million) capital fund out of Germany has closed and is looking for “ground-breaking” heart disease tech.